Homepage
Author:
Windward Bio
Posted Date:
June 9, 2026
Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378
Windward Bio
June 9, 2026
Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
Windward Bio
May 4, 2026
